Lembas registers a 35-person dietary-supplement trial for prediabetes
The Not Applicable-phase study will test Lembas Edge's tolerability and its effect on post-meal blood sugar against placebo in a small Canadian cohort.
Executive Summary
- Lembas has registered a two-part interventional study of its Lembas Edge product, evaluating tolerability and its effect on blood sugar after meals in adults with prediabetes and obesity. The trial carries a Not Applicable phase designation, consistent with a dietary-supplement intervention rather than a drug development program.
- The study is small and randomized with multiple arms, structured first to assess safety and lab-value shifts, then to measure glucose and hormone responses against placebo across a range of doses.
- The trial enters a prediabetes and obesity landscape populated by injectable and oral GLP-1-class programs from major pharmaceutical sponsors, none of which shares Lembas Edge's modality.
- The study has not yet begun enrolling, and its outcome will show whether a supplement-based approach can produce a measurable glycemic signal in a field currently defined by incretin pharmacology.
The trial
Lembas has added a new study to ClinicalTrials.gov titled "A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control," registered under NCT07711288. The trial is not yet recruiting, with a planned start date of September 1, 2026, and a primary completion date of January 1, 2027. It will enroll 35 participants across four arms in Canada, using a randomized, quadruple-masked design. The intervention is classified as a dietary supplement, and the trial carries a Not Applicable phase designation, the standard registry classification for non-drug interventional studies rather than a drug-development phase. NCT07711288A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic ControlNCT07711288
How it was done
The study runs in two parts. Part 1 tracks tolerability over 14 days, measuring changes in blood counts, liver enzymes, kidney function, electrolytes, vital signs, and adverse events after supplementation. Part 2, spanning visits from day 1 to day 22, measures the difference in postprandial glucose, using incremental area under the curve over zero-to-120 and zero-to-240 minute windows, between three doses of Lembas Edge and placebo. Secondary measures include postprandial insulin and self-reported satiety, and exploratory measures include the gut hormones GIP, GLP-1, and PYY. The design pairs a short safety run-in with a placebo-controlled crossover-style glycemic challenge. NCT07711288A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic ControlNCT07711288
Competitive context
The prediabetes and obesity field this trial enters is populated by pharmaceutical incretin programs rather than supplements. Eli Lilly, Novo Nordisk, and AstraZeneca are each running Phase 3 or Phase 4 trials in obesity or related metabolic indications with tirzepatide, retatrutide, semaglutide, CagriSema, and elecoglipron, all built around GLP-1 receptor or related incretin-pathway pharmacology. Lembas Edge's molecular target and mechanism are not established in the trial record, so no mechanism-based comparison to these programs is possible. The trial instead sits in the same indication space as a modality outlier: a dietary supplement tested for a glycemic effect in a field where drug candidates dominate late-stage development.
What's ahead
No results have posted for NCT07711288, and the trial has not yet opened enrollment. Its registry-tracked amendment history and stability profile show no changes since registration. The readout, when it lands, will test whether a supplement can produce a measurable postprandial glucose or insulin effect against placebo, a considerably lower bar than the weight-loss and glycemic thresholds that Phase 3 incretin trials in the same indication are built to clear. NCT07711288A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic ControlNCT07711288
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.